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Abstract During the last decades, numerous studies have
focused on combining the unique catalytic/functional
properties and structural characteristics of proteins and
enzymes with those of synthetic molecules and macro-
molecules. The aim of such multidisciplinary studies is to
improve the properties of the natural component, combine
them with those of the synthetic, and create novel
biomaterials in the nanometer scale. The specific coupling
of polymers onto the protein structures has proved to be one
of the most straightforward and applicable approaches in
that sense. In this article, we focus on the synthetic
pathways that have or can be utilized to specifically couple
proteins to polymers. The different categories of well-
defined protein–polymer conjugates and the effect of the
polymer on the protein function are discussed. Studies have
shown that the specific conjugation of a synthetic polymer
to a protein conveys its physico-chemical properties and,
therefore, modifies the biodistribution and solubility of the
protein, making it in certain cases soluble and active in
organic solvents. An overview of the applications derived
from such bioconjugates in the pharmaceutical industry,
biocatalysis, and supramolecular nanobiotechnology is
presented at the final part of the article.
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Introduction
Among the most stimulating challenges for the scientists of
our times is the understanding and exploitation of Nature’s
vast machinery to create novel, efficient biotechnological
devices. Along these lines, the covalent attachment of
single or multiple polymeric chains onto biomolecules has
been an area of intense research during the last decades
(Veronese 2001; Pennadam et al. 2004; Veronese and Pasut
2005; Vriezema et al. 2005).
The creation of such chimeric systems offers the exciting
possibility of combining the properties of both the biological
and the synthetic component in a new class of biomaterials
designed to perform otherwise impossible functions/actions.
Theoretically, the properties of the protein–polymer hybrids
should simply be a synergistic combinatorial function of
those of each individual component and should ideally lead
to overcoming some of their intrinsic limitations. This
assumption has been especially pursued in the area of
pharmaceutics where one of the holy grails is still the
stabilization and enhancement of the action of therapeutics
(proteins and drugs) without comprising their stability
(Ulbrich et al. 1996; Omelyanenko et al. 1996; Maeda
2001a,b; Youngster et al. 2002; Caliceti and Veronese
2003). Furthermore, assemblies incorporating biological
components are particularly attractive as supramolecular
biomaterials, lab-on-a-chip components and as building
blocks in microfluidics and bioprocessing applications (van
Hest and Tirrell 2001; Niemeyer 2001; Shimoboji et al.
2002; Pennadam et al. 2004; Klok 2005).
The protein–polymer conjugates that are highlighted in
this review are well-defined and differ from other bioadducts
in the sense that the protein-to-polymer ratio is predefined
and the position of the conjugation site is precisely known.
From the chemical point of view, these bioconjugates are in
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fact diblock copolymers, which, by design, have signifi-
cantly higher molecular weights and volumes than their
synthetic counterparts. Furthermore, as Nature synthesizes
its biopolymers with high efficiency, these synthetic bio-
diblocks have an intrinsic structural advantage over the
synthetic block copolymers by possessing a monodisperse
block (the protein). The incorporation of the biological
component in the copolymer structure therefore offers new
perspectives for creating biomacromolecules that comprise
the biological properties of the protein component with the
chemical and assembling properties of the polymer.
From the biological point of view, the conjugation of a
polymer can either alter or preserve many of the important
protein biological functions, such as enzymatic activity or
receptor recognition, depending on the overall resulting
structure. In principle, such conjugation masks the protein
surface and increases its molecular size in ways that reduce
its renal ultrafiltration, prevent the approach of antibodies
or antigen processing cells, and reduce the degradation by
proteolytic enzymes. Finally, upon conjugation the synthet-
ic polymer is expected to convey its physico-chemical
properties and thus modify also the biodistribution and
solubility of the protein or enzyme. This offers the
possibility of creating synthetic enzymes that are soluble and
active in organic solvents, of developing new techniques in
biocatalysis, and most importantly, of advancing in pharma-
ceutical technology and supramolecular nanobiotechnology.
It is worth mentioning that the synthesis of well-defined
protein–polymer biohybrids falls under the umbrella of
specific protein functionalization studies. This area has
been in the spotlight of academic research for several
decades now and continues to flourish and serve as one of
the main knowledge foundations for the understanding of
biomolecules to successfully employ them. The bibliogra-
phy in this area is vast (Matthews et al. 1991; Hermanson
1996; DeSantis and Jones 1999; Qi et al. 2001) but out of
the scope of this review paper.
Methods for specific protein functionalization
The holy grail of bioconjugate chemistry is to develop
efficient methods for the modification of proteins and other
biological molecules with a high degree of specificity in
vitro and in vivo. No such magic bullet universal technique
exists to date, but significant advances have been made in
the development of techniques that fulfill the above criteria
under specific conditions. Proteins can be chemically
modified using a range of methods (Hermanson 1996). In
this review, we will only focus on those that have been
successfully used to modify proteins with polymers in a
specific, programmed manner. We can broadly divide these
into three major categories: a) methods for direct specific
functionalization, b) methods for indirect specific function-
alization, and c) methods for specific functionalization via
cofactors/ligands (Fig. 1). It should be noted that the only
difference between methods a) and b) is that in the former,
the polymer is introduced directly onto the protein structure
while in the latter, a heterobifunctional spacer is first linked
to the protein to create a reactive biohybrid, which is
subsequently further functionalized by the attachment of a
polymer onto the spacer.
Choosing the appropriate method to functionalize a
protein is no easy task. The most useful protein function-
alities for specific chemical modification are the natural
amino acids side chains of cysteine (Cys), lysine (Lys),
tyrosine (Tyr), and glutamine (Gln) together with the α-N
terminus (α-N) of the peptide backbone. Directed tech-
niques for the introduction of non-natural amino acids into
proteins using methods such as non-ribosomal peptide
synthesis, peptide ligation (Hodgson and Sanderson
2004), and tRNA engineering methods (Hodgson and
Sanderson 2004; Budisa 2004) have somewhat broadened
the range of available functionalities, although their use is
still quite limited. Recently, proteins have also been
selectively modified via their genetically engineered His-Tags
(Meredith et al. 2004).
Another consideration in this paper is the complemen-
tary reactive group(s) for these natural and non-natural
amino acids (vide supra), which must be available on the
target polymer or heterofunctional spacer. Practical consid-
erations such as chemical compatibility or economic factors
may often rule out certain bioconjugate routes. More often,
it is the availability of the target functional group on the
protein that determines the route taken. The target has to be
reasonably exposed on the surface of the protein and not
buried in the interior of the ternary protein structure. In the
case that two or more amino acid side chains (e.g., Lys) are
exposed, it becomes very difficult to control the bioconju-
gation reaction in such a way that only one specific linker
between the protein and the target is created. Finally, the
modification should ideally have little or no effect on the
protein conformation and function, e.g., catalytic activity
and specificity. It is, therefore, clear that detailed structural
information is a pre-requisite for the successful selective
functionalization of proteins. In practice, this usually
requires information about their three-dimensional structure
via single-crystal X-ray and/or solution NMR studies,
although the protein sequence might be sufficient, provided
that some structural information is available.
The most popular but least specific of the above-
mentioned methods is coupling to the ɛ-amino group on a
lysine residue (Lys) or the N terminus (α-N) of the protein
(Fig. 2). The ɛ-amine group on Lys and α-N can react very
efficiently with a number of functional groups, including
aldehydes and activated carboxylic acids. The reaction of
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Lys and/or the α-N terminus with aldehydes results in the
reversible formation of a Schiff base (imide), which can in
turn be reduced with NaCNBH3 to form a secondary amine
linker. Numerous methods are available to activate carbox-
ylic acids for the reaction with Lys and α-N terminus,
among which N-hydroxysuccimide (NHS) activation is
usually the method of choice (Veronese and Pasut 2005).
Both of these amine-modifying methods have advantages
and disadvantages. Using NHS-activated carboxylic-acid-
terminated polymers or spacers is straightforward, but the
selectivity of the reaction is low. This problem is
augmented by the fact that many proteins have several
Lys on their surface, in addition to the often exposed α-N
terminus. As the ɛ-amine group on Lys and α-N terminus
have different pKa, (about 10 and 7.8, respectively; Klok
2005), their difference in reactivity towards activated
carboxylic acids could be utilized for the selective
functionalization of the α-N-ternimus. In practice, however,
this is somewhat difficult (Wetzel et al. 1990; Gaertner and
Offord 1996).
This difference in reactivity is more useful in reactions
involving aldehyde-functionalized polymers and hetero-
functional crosslinkers as only the α-N terminus will react
with these at pH=5 (Kinstler et al. 1996; Veronese and
Pasut 2005; Klok 2005). Another advantage of using this
method is that it will maintain the overall charge of the
protein, while the use of activated (NHS) carboxylic acids
results in the loss of one positive charge when the new
amide bond is formed (Veronese and Pasut 2005). The main
disadvantages of the aldehyde method are that it is a two-
step procedure and that aldehyde synthesis is often even
more challenging than that of carboxylic-acid-terminated
polymers or heterofunctional spacers. Recently, a variation
of this method has been developed using an iridium catalyst
to carry out this reduction in situ and sodium formate as the
hydride source (McFarland and Francis 2005).
The thiol side chain in cysteine (Cys) is a mild
nucleophile—a fact that has been extensively utilized for
the specific chemical modification of proteins. Under the
appropriate conditions, Cys can be modified selectively,
rapidly, and in a quantitative fashion. Another advantage of
targeting the Cys residue is that it is rare in proteins while
most of them contain only one accessible Cys. Broadly
speaking, the Cys modification reactions can be divided
into alkylation and disulfide formation. In both cases, the
overall charge of the protein is maintained, adding to the
advantages of targeting Cys.
Alkylation of Cys can be achieved using either α-halo
(usually iodine) carbonyl compounds or maleimides. Partial
deprotonation of the thiol in Cys at pH 9–10 allows the
formation of thioethers using α-halo carbonyl compounds,
while Cys can also be modified at neutral pH (6.8–7.0)
using maleimide-functionalized groups as Michael accep-
tors (Hodgson and Sanderson 2004). Of the two methods,
Fig. 1 Methods for specific protein functionalization: a direct functionalization, b indirect functionalization, and c functionalization via cofactors/
ligands
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the latter prevails for the modification of proteins with
polymers (Veronese and Pasut 2005) given the milder
conditions, greater specificity (both can side-react with
other amino acids, but maleimides will only react with
amines at pH >8), but, first and foremost, the better
reactivity of maleimide. This is quite important, as Cys is
rather hydrophobic and is often found partially or fully
buried within the protein structure.
Disulfide formation, especially with polymers and
heterofunctional spacers terminated with the o-pyridyldi-
sulfide group, is the most specific method for functional-
ization of Cys. It is also a fully reversible reaction through
the use of standard reducing agents such as dithiothreitol
(DTT), which can be regarded as an advantage or
disadvantage depending on the application. DTT can also
be used to expose more Cys in the protein by cleaving
disulfide bridges, although the structural and functional
integrity of the proteins needs to be checked carefully after
this treatment, given the important role that disulfide
bridges play in protein structures (Velonia et al. 2002;
Heredia et al. 2005).
The third most important amino acid for specific protein
functionalization is tyrosine (Tyr). The nucleophilic char-
acter of Tyr is greatly enhanced under mildly basic
conditions (pH >8.5) that deprotonate the Tyr phenol side
chain. The most commonly used methods for modifying
Tyr include iodination and reactions with diazonium salts
(Hermanson 1996). A number of alkylation and acylation
reactions for modifying Tyr can also be carried out, but
these have not gained momentum due to cross-reactivity
towards Cys and/or Lys often combined with the need for
quite harsh conditions. Significant advantages have been
recently achieved in this area, mostly due to the work of
Francis and co-workers (Joshi et al. 2004; Schlick et al.
2005; Tilley and Francis 2006). This group has developed
several mild and highly selective methods for the modifi-
cation of Tyr. One of these involves a three-component
Mannich-type reaction between Tyr, an aliphatic aldehyde
and an aniline derivative (Joshi et al. 2004). This reaction
proceeds smoothly and at nearly neutral pH (6.5), provided
a large (×1,000) excess of the synthetic aldehyde and
aniline is used. Another method requires only a moderate
excess (×5) of the synthetic partner when a palladium
catalyst is used to couple a π-allyl species to Tyr under
mildly basic conditions (Tilley and Francis 2006).
Glutamine (Gln) is also a unique type of target for
selective functionalization of proteins, which proceeds
using the enzyme transglutaminase (TGase) to mediate the
reaction. This enzyme catalyzes the cross-linking reaction
between Gln and various primary amines, including the Lys
side chain (Sato 2002). TGases are highly selective towards
the target Lys and will only catalyze this reaction if the
primary amine is highly exposed. This biosynthetic ap-
proach can be utilized to introduce PEG-polymers and other
synthetic targets, provided they contain an exposed long
aliphatic primary amine such as the aminobutane
functionality.
All the methods discussed above for the direct specific
functionalization of proteins (Fig. 1a) can also be used for
the indirect specific functionalization of proteins (Fig. 1b).
It should be noted that “indirect” in this context refers to the
target group (e.g., polymer) not reacting directly with the
protein but rather being linked via a secondary non-natural
functionality that is initially introduced to the protein
structure by a specific functionalization. A simple example
would include heterobifunctional spacers such as an NHS-
activated carboxyl acid spacer terminated with a maleimide
group. This spacer could be used to functionalize the ɛ-
amine group of Lys or the α-N terminus of a protein and
would be followed by a second reaction with a thiol-
terminated target compound. When linking polymers to
proteins, these simple heterofunctional groups are usually
used to avoid the problems associated with lack of
reactivity when two large molecules are brought together
(the protein and the polymer). Heterofunctional spacers
designed for protein cross-linking (e.g., the NHS-activated
maleimide above) are often used to circumvent this
problem; however, these have to be chosen with care to
avoid intra- or intermolecular cross-linking in the protein of
interest.
Recent heterofunctional spacers that bear functionalities
such as azides and alkynes (in position 1), which do not
react with natural amino acids, have also been used to
couple a secondary target with a high degree of selectivity
through click-chemistry techniques (Fig. 3; Kolb et al.
2001; Köhn and Breinbauer 2004). The latter include the
aqueous version of the [3+2] Huisgen cycloaddition (Lewis
et al. 2002) and the modified (non) traceless Staudinger
ligation (Saxon et al. 2000; Kiick et al. 2002; Köhn and
Breinbauer 2004). Methods that allow the expansion of the
genetic code to include non-natural amino acids, including
those bearing azides or alkynes in the expressed proteins
(Budisa 2004; Wang and Schultz 2005), have allowed the
use of click chemistry techniques for the subsequent direct
functionalization of these genetically modified proteins. In
another approach for indirectly modifying proteins,
reported by Francis et al., Tyr was initially modified with
a p-diazonium salt derived from p-aminoacetophenone. The
ketone-modified bioconjugate was then converted to a
range of bioconjugate oximes by reaction with a series of
alkoxyamines, including polymeric oximes (Schlick et al.
RFig. 2 Methods for the direct specific protein functionalization on the
natural amino acids side chains of cysteine (Cys), lysine (Lys),
tyrosine (Tyr), and glutamine (Gln) together with the α-N terminus
(α-N) of the peptide backbone
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2005). Finally, proteins have also been specifically modi-
fied with an initiator suitable for atom transfer radical
polymerization (ATRP), to create a protein–polymer conju-
gate, which was then used to achieve ATRP polymerization
reactions (Heredia et al. 2005; Lele et al. 2005).
Protein cofactors and ligands (Fig. 4) such as the heme
(porphyrin), FAD, NAD(P)+, and biotin (vitamin B7) are
also attractive targets for specifically modifying protein
structures (Fig. 1c). The main advantage of modifying low-
molecular weight cofactors and ligands is that this can be
done using traditional synthetic and purification techniques,
including organic solvents and silica gel chromatography.
After purification, these modified cofactors and ligands are
simply mixed with the apo-protein and the resulting
reconstituted bioconjugate purified by dialysis or size-
exclusion chromatography. This approach is efficient,
provided the cofactor/ligand modification does not impede
the reconstitution of protein or the binding to it. Biotin has
proved to be the simplest and easiest ligand to work with,
as its carboxylic acid terminus can be modified at will
without having much effect on binding to the avidin family
of proteins. The heme group can also be modified via its two
propionic acid side chains, and modified hemes have been
successfully introduced into myoglobin, hemoglobin, cyto-
chrome b562, and related proteins (Hamachi and Shinkai
1999). The adenine family of cofactors, including NAD(P)+
( Bückmann and Carrea 1989) and FAD (Bückmann et al.
1997), can be functionalized on the adenine ring, leaving
intact the active nicotinamide or flavin part of these
cofactors. Aminoethyl-appended NAD, for instance, has
been successfully modified with both PEG and dextran
without significant loss of its cofactor activity with yeast
alcohol dehydrogenase, compared with that of the actual
NAD (Bückmann et al. 1981).
Well-defined protein–polymer biohybrids
PEGylated proteins
Protein PEGylation is undeniably the most extensively
studied area of specific polymer conjugation, as it has been
Fig. 3 Click-chemistry direct specific protein functionalization
approach
Fig. 4 Cofactors and ligands used for protein modification. The
arrows point to common modification sites
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proven to be one of the most straightforward procedures for
enhancing the therapeutic and biotechnological potential of
peptides and proteins (Hooftman et al. 1996; Kodera et al.
1998; Veronese 2001; Roberts et al. 2002; Caliceti and
Veronese 2003; Veronese and Pasut 2005; Haag and Kratz
2006; Fee and Van Alstineb 2006). Many therapeutic
proteins have been conjugated with poly(ethylene glycol)
(PEG) to enhance their pharmacological properties both in
vivo and in vitro, since its applicability was first demon-
strated in 1977 (Abuchowski et al. 1977). The exhaustive
list of methods and applications of protein PEGylation is
beyond the scope of this review and already well
documented elsewhere. With the established methodology
and the numerous applications of PEGylated proteins such
as PEG-Intron for Hepatitis C and the FDA filing of
Pegasys (PEG-IFN-alpha 2a) and PEG-Neupogen (PEG-G-
CSF) already in the market, the effect of mono- vs poly-
substitution on the properties of the biohybrids is even
more pronounced.
Several examples demonstrate the importance of mono-
PEGylation in the properties of the resulting hybrids; perhaps
the most pronounced of which is the PEG-Intron, which
results from the monoPEGylation of an interferon by a 12-
kDa PEG (Wang et al. 2002). In this case, the modification of
the interferon with only one polymer chain was found to be
responsible for its successful pharmacological action. It is
also worth mentioning the example of mono-PEGylation of a
lysine-deficient tumor necrosis factor (TNF), which was
performed at the N terminus to avoid PEGylation of lysine
residues close to the active site in the natural form
(Yamamoto et al. 2003). Site-directed mutagenesis was
exploited to control PEGylation and the resulting activity
of the protein interleukin (Pettit et al. 1996) as well as to
insert a free cysteine group into human Fv fragments and
further couple the resulting free thiol with a maleimide-
activated PEG (Yang et al. 2003). Finally, in a more exotic
approach, Sato and coworkers used enzymatic catalysis with
microbial transglutaminase for site-specific PEGylation of
recombinant interleukin-2 (Sato 2002). There have also been
reported cases, however, where the multi-functionalization of
a protein was responsible for attaining the required action
(Heathcote et al. 1999). The main benefit for the latter was
that multi-PEGylation allowed the use of PEGs with lower
molecular weights, which may be more rapidly cleared from
the body.
Proteins specifically linked to stimuli-responsive polymers
The conjugation of proteins with stimuli responsive, or
“smart” polymers, as named by R. Dagani (Dagani 1995)
due to their ability to mimic the nonlinear response of
biopolymers as a result of the cooperative interaction
between monomers, has been thoroughly investigated by
several groups. These stimuli-responsive polymers undergo
a reversible change in size and hydrophobicity in response
to external stimuli such as temperature and/or pH. The
coupling of smart polymers to various proteins has been
performed both randomly (Cole et al. 1987; Nguyen and
Luong 1989; Chen and Hoffman 1993; Galaev and
Mattiasson 1993; Ding et al. 1998; Mantovani et al. 2005)
and at specific sites of the protein structure (Ding et al.
1999; Bulmus et al. 2000).
Hoffman and his collaborators mainly employed the
tetrameric protein streptavidin and genetically engineered
mutants of this protein in their studies and specifically
coupled it with a biotinylated PNIPAAm at temperatures
below the lower critical solution temperature, LCST. Upon
the formation of the biohybrid macromolecules, the authors
demonstrated that a change in the physical properties of the
polymer through small external changes in temperature or
pH could be used to reversibly control biotin and
biotinylated macromolecule access to, and/or release from,
smart polymer–streptavidin bioconjugates (Stayton et al.
1995; Ding et al. 1999; Bulmus et al. 2000; Ding et al.
2001; Shimoboji et al. 2001). It was for the first time also
demonstrated that smart polymers could act as molecular
switches (gates) in an attempt to control protein activity. By
using a site-specific poly(N,N-diethylacrylamide)/streptavi-
din conjugate, it was further shown that the blocking of
biotinylated proteins was size-selective. Gating was found
to be sensitive to the size of the protein, e.g., the immuno-
γ-globulin, IgG (150 kDa) was unable to bind below and
above LCST, the protein G (6.2 kDa) was found to bind at
all temperatures, but bovine serum albumin, BSA (67 kDa),
could only bind at temperatures above LCST, where the
polymer was collapsed. In summary, the authors proved
that below the LCST, the polymer sterically interferes with
the access to the adjacent binding site acting as a “polymer
shield”, whereas above the LCST, polymer collapse
exposes the adjacent site (Ding et al. 2001).
Extremely interesting behavior was observed by
biohybrids resulting from the specific coupling of the
temperature-responsive and photoresponsive DMA-co-4-
phenylazophenyl acrylate (DMAA) and DMA-co-N-4-
phenylazophenyl acrylamide (DMAAm), to an N55C
mutant of the commercially important endogluconase 12A
(EG 12A) from Trichoderma reesei (Shimoboji et al. 2002).
The above-mentioned copolymers display inverse phase
transitions in response to UV and VIS light irradiation
together with temperature-responsive LCST behavior. In-
terestingly, their LCSTs are shifted in opposite directions
under UV vs VIS illumination. These opposite photo-
induced phase transitions of DMAA and DMAAm were
used to engineer molecular switches that turn “on” EG 12A
as DMAA becomes hydrated and expands with VIS light,
and “off” with UV light as the DMAA coil becomes
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hydrophobic and collapses, with the opposite responses for
DMAAm. The conjugates both displayed almost a com-
plete lack of activity when the polymers were in their
collapsed state, and when the UV or VIS light stimulated
the rehydration and expansion of the polymer coil, the
conjugates displayed approximately 60% of the activity of
the unconjugated enzyme. Furthermore, the photoswitching
was found to be reversible and could be cycled between the
active on- and the inactive off-state and proved to be
efficient both when the conjugate was free in solution or
immobilized on magnetic beads. In such a system, the
photo-responsive polymers serve jointly as antennae and
actuators that reversibly respond to distinct optical signals
to switch the polymer–enzyme conjugates on and off. The
ability to photo-regulate enzyme activities provides exciting
opportunities in the fields of bioprocessing, diagnostics,
and microfluidics.
Giant amphiphiles
The innovative class of bio-surfactants consisting of a
protein or an enzyme linked to a hydrophobic polymer, i.e.,
the giant amphiphiles, was extensively studied by Nolte
and collaborators following different approaches (Fig. 5,
Velonia et al. 2002; Boerakker et al. 2002; Hannink et al.
2001). Using the well-established streptavidin-biotin ap-
proach, monolayers of giant amphiphiles were constructed
by the association of biotinylated polystyrene with strepta-
vidin (Fig. 5c, Hannink et al. 2001). The manner in which
these giant amphiphiles were synthesized left two of the
streptavidin binding sites unoccupied. These sites were
subsequently used to create functionalized amphiphiles by
the binding of a biotinylated form of the iron storage
protein ferritin or horseradish peroxidase.
Nolte and coworkers also reported on the synthesis and
characterization of well-defined biohybrids through cova-
lent coupling of a polymer directly to the enzyme (Velonia
et al. 2002). To achieve the covalent coupling in a
predefined position, a disulfide bridge exposed in the
surface of the lipase B from Candida antarctica (CALB)
was specifically reduced to provide two readily functiona-
lizable thiol groups. A maleimide capped polystyrene was
attached to the enzyme (in a THF/water mixture) to afford
micrometer-long fibers that retained part of the catalytic
activity of the enzyme head group (Fig. 5a). This was the
first example reported in bibliography, of a giant amphi-
phile exhibiting aggregation behavior similar to that of the
traditional amphiphiles and the block copolymers.
Responsive polymers, were also employed for the
formation of giant amphiphiles. Uludag et al. have
synthesized NIPAAm polymers that contain protein-reac-
tive N-acryloxysuccinimide and LCST-altering, hydropho-
bic alkylmethacrylates to obtain thermo-responsive,
protein-conjugating polymers. The thermo-sensitive poly-
mers were capable of coupling with a co-injected therapeu-
tic protein and retain it at an application site where tissue
regeneration was required. Such bioconjugates might,
therefore, be applied for drug delivery (Uludag et al. 2001).
An alternative approach to the synthesis of giant
amphiphiles makes use of the cofactor/enzyme self-assem-
bly found in Nature. In this case, the giant amphiphile
construction was accomplished through the direct coupling
Fig. 5 Morphologies reported
for giant amphiphiles:
a CALB-polystyrene micellar
rods (Reprinted with permission
from Velonia et al. 2002;
Copyright 2002 ACS
Publications), b horseradish
peroxidase polystyrene vesicles
(Reprinted with permission
from Boerraker et al. 2002;
Copyright 2002 Wiley-VCH),
c streptavidin monolayers,
(Reprinted with permission
from Hannink et al. 2001;
Copyright 2002 Wiley-VCH).
d BSA-polystyrene vesicles
and CALB-polystyrene tubular
structures
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of a polymer to the cofactor of an enzyme followed by the
subsequent reconstitution of the apoenzyme around the
functionalized cofactor. This method was employed by
Nolte and coworkers to create and study polystyrene
horseradish peroxidase biohybrids (Boerakker et al. 2002).
The desired biohybrid amphiphiles were prepared by
adding a THF solution of the functionalized polymer to
an aqueous solution of the apoenzyme. Electron microsco-
py (Fig. 5b) revealed the formation of vesicular aggregates
with diameters of 80–400 nm. In most cases, these
aggregates enclosed spherical objects, often located away
from the center of the aggregates. To explain these
structures, the authors assumed that the hemin-functional-
ized polymer initially forms aggregates on to which the
apo-HRP can be reconstituted in the form of the biohybrid.
More specifically, these structures arise from vesicles
growing from the polystyrene aggregates in such a way
that they enclose the initial aggregate. No activity could be
observed when HRP was reconstituted at 4°C to form the
bioassemblies. However, when the reconstitution of apo-
HRP was carried out at 22°C, the enzyme–polymer hybrid
surprisingly regained activity.
One newly reported category of biohybrid amphiphiles is
the metal-to-ligand coordinated giant amphiphiles that
combine the properties of a functional biocopolymer, with
the versatility of a metallo-supramolecular copolymer
(Fig. 5d, Velonia et al. 2003, 2004). In this modular
approach the proteins/enzymes (BSA/CALB) were initially
functionalized with a 2.2′:6′, 2″-terpyridine moiety to
afford terpyridine functionalized biohybrids, which were
characterized using MALDI. The formation of protein-
polymer giant amphiphiles as asymmetric Ruthenium(II)
functionalized metal complexes was in turn performed by
adding a THF solution of mono-metallated-terpyridine-
appended polystyrene. As in the case of previously
reported biohybrids, these novel giant soaps were found
to aggregate in manners similar to that of molecular
amphiphiles. Interestingly, the superstructures formed by
this modular approach significantly differed from those in
the analogous amphiphiles formed by the direct coupling
of the polymer to the protein surface. This new synthetic
approach paved the way to the alternative pathway of
constructing a plethora of biohybrids through the initial
functionalized protein and coordination chemistry.
Furthermore, in very recent communications, Nolte
and coworkers have reported that click chemistry, i.e., the
Cu(I) catalyzed [3+2] Huisgen cycloaddition, can also be
used for the synthesis of a biohybrid BSA-PS giant
amphiphile (Dirks et al. 2005) and a BSA-lipase biohybrid
(Hatzakis et al. 2006).
Interestingly, in all the above-mentioned pilot studies,
the giant amphiphiles were found to exhibit assembling
properties analogous to those of synthetic copolymers and
molecular amphiphiles and to retain part of the catalytic
activity of the enzyme head group. While the methodology
for their synthesis and characterization has been developed,
the influence of the composition of the different compo-
nents to the overall architecture of the assemblies and to the
catalytic properties of the head group remains to be studied.
Applications
Most of the applications arising from the creation of
polymer–protein hybrids are found in pharmaceuticals and
medicine and mainly concern PEGylated proteins. As
mentioned above, PEGylated proteins usually display
increased plasma half-life, due to the increase of both their
stability and solubility caused by the polymer. The latter,
termed as enhanced permeability and retention (EPR)
effect, has already been used since the 1980s to create
passive anticancer agents (Maeda et al. 1992, Maeda
2001a) and has been the theme of intense studies in the
last decade leading to several novel PEGylated anticancer
agents that are currently in the stage of clinical trials
(Duncan 2003).
The stimuli responsive polymers have also already
found interesting applications in the areas of protein
isolation/separation. The extensively studied thermo-re-
sponsive protein conjugates are used in selectively
precipitating/solubilizing proteins, a procedure that is
used to facilitate protein purification or its easy recovery
from a reaction mixture (Hoffman et al. 2000). In the
category of the protein-responsive polymer biohybrids, one
of the most exciting applications derives the controlled
release of biotin from a poly(N,N-diethylacrylamide)/strep-
tavidin conjugate leading to responsive biomolecular
switches (Ding et al. 2001). Similar results were observed
when the photo-responsive DMA-AZAAm copolymer
collapsed and blocked substrate access upon UV irradiation.
(Shimoboji et al. 2002).
PEGylation has also led to the synthesis of protein
hybrids with interesting biotechnological applications
through the increase of their solubility and stability in
organic solvents (Kodera et al. 1998). Several PEGylated
proteins and enzymes have been studied and found to be
catalytically active in organic solvents such as benzene or
chloroform (Takahashi et al. 1984) or possess an increased
stability that is a prerequisite for the formation of
bioreactors and biosensors (Ohno and Yamaguchi 1994).
Conclusions
Research into polymer–protein conjugation has come a
long way since the first papers on PEGylated proteins in the
1970s (Abuchowski et al. 1977; Kodera et al. 1998). Early
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works in this field focused on improving the pharmacolog-
ical properties of proteins for their use in medicine. The
unique material and catalytic properties of proteins and
enzymes were also recognized very early in the fields of
organic/bioorganic chemistry, where their modification was
initially aimed at stabilization and improvement of their
catalytic action, including their use in organic solvents. In
these early attempts, the site and degree of polymer
modification on the target protein was poorly controlled.
Nowadays, to obtain an FDA approval, the composition of
the synthetic protein–polymer hybrids must be clearly
defined (Veronese and Pasut 2005), thus increasing the
need for highly specific modifications, especially in the
fields of medicine and pharmaceuticals.
During the last decades, the advances in molecular
biology, biotechnology (protein expression, site-directed
mutagenesis), polymer chemistry, physicochemical, bio-
imaging and characterization (especially mass spectrome-
try) techniques, have led to an impressive development of
methods for the specific modification of proteins and the
characterization of the resulting chimeric macromolecular
structures. Several well-designed protein pharmaceuticals
are already in the market, while rapid growth is also
observed in the area of the development of polymer–protein
conjugates with preprogrammed functions. This includes
both “smart” polymer–protein conjugates and polymer–
protein giant amphiphiles that are preprogrammed to self-
assemble into well-defined nanostructures.
Nanoscale self-assembly and response to external
stimuli are hallmarks of natural systems, and modifying
proteins to achieve such properties has enormous poten-
tial. Nature provides a wide variety of proteins and
enzymes possessing a continuum of material and func-
tional properties. The programmed utilization of their
chemical and topographical properties through specific
modification will allow building novel nanometer- and
micrometer-sized devices, as well as developing biomate-
rials that mimic various natural processes or that can be
used as components for lab-on-a-chip applications
(Niemeyer 2001; Seeman and Belcher 2002; Sarikaya et
al. 2003; Zhang 2003; Velonia et al. 2005). These would
include bio-mimetic sensors, environmentally responsive
biomaterials for applications in microfluidics and tissue
engineering together with bio-mimetic energy conversion,
light-harvesting, signal transduction, and pollutant degra-
dation. Clearly, we are still far from biotechnological
building devices with the efficiency of Nature, but
systematic fundamental and interdisciplinary research using
polymer-modified proteins appears an obvious choice
towards achieving these targets.
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